InsiderSignal.AI

InsiderSignal.ai

NUVL - Nuvalent, Inc.

Insider Sale by Noci Darlene (Chief Development Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Noci Darlene, serving as Chief Development Officer at Nuvalent, Inc. (NUVL), sold 5,500 shares at $97.81 per share, for a total transaction value of $537,943.00. Following this transaction, Noci Darlene now holds 58,117 shares of NUVL.

This sale represents a 9.00% decrease in Noci Darlene's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 30, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 1, 2026, 2 days after the trade was made.

Nuvalent, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Noci Darlene

Noci Darlene

Chief Development Officer

Darlene Noci is the Chief Development Officer at Nuvalent, Inc. (NUVL), a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology, particularly ROS1-positive and ALK-positive NSCLC.[[5]](https://www.sec.gov/Archives/edgar/data/0001861560/000095017025059295/nuvl-20250425.htm)[[6]](https://www.prnewswire.com/news-releases/nuvalent-outlines-pipeline-and-business-progress-reiterates-key-anticipated-milestones-and-reports-fourth-quarter-and-full-year-2024-financial-results-302386850.html) In this role, she oversees global product development, regulatory affairs, and strategic initiatives, including pivotal trials like ARROS-1 and ALKOVE-1, with topline data expected in 2025 and an NDA submission planned for mid-2025 for zidesamtinib.[[6]](https://www.prnewswire.com/news-releases/nuvalent-outlines-pipeline-and-business-progress-reiterates-key-anticipated-milestones-and-reports-fourth-quarter-and-full-year-2024-financial-results-302386850.html) Noci holds an A.L.M. degree, noted as a graduate degree from Harvard University, and previously served as General Counsel at AVEO Pharmaceuticals, Inc.[[2]](https://www.marketscreener.com/insider/DARLENE-NOCI-A2UPBA/)[[5]](https://www.sec.gov/Archives/edgar/data/0001861560/000095017025059295/nuvl-20250425.htm) With over 20 years of experience as a global product development leader specializing in regulatory affairs, Noci has demonstrated expertise in advancing therapies through clinical development and regulatory pathways.[[1]](https://theorg.com/org/nuvalent/org-chart/darlene-noci) She recently engaged in insider trading at Nuvalent, reflecting her significant stake in the company's success.[user context] Her leadership emphasizes patient access, including global Expanded Access Programs for zidesamtinib and neladalkib.[[6]](https://www.prnewswire.com/news-releases/nuvalent-outlines-pipeline-and-business-progress-reiterates-key-anticipated-milestones-and-reports-fourth-quarter-and-full-year-2024-financial-results-302386850.html)

View full insider profile →

Trade Price

$97.81

Quantity

5,500

Total Value

$537,943.00

Shares Owned

58,117

Trade Date

Monday, March 30, 2026

6 days ago

SEC Filing Date

Wednesday, April 1, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Nuvalent, Inc.

Company Overview

No company information available
View news mentioning NUVL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5283352

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime